Genitourinary Cancers

• Participant Clinical Case Discussion: Meningism in a patient with Urothelial Cancer "When you have excluded the impossible.."
• Cabazitaxel Benefit Demonstrated For metastatic CRPC Patients
• Olaparib May Have PROfound Effect On mCRPC
• GU prostate
• GU non-prostate
• Invited Discussant LBA12_PR
• Invited Discussant LBA13
• Invited Discussant LBA14_PR
• CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate canc...
• PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous...
• IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs p...
• Presentation of case/condition
• Is there a role for radical surgery?
• Advances in pelvic nodal radiotherapy
• Systemic treatment: The role of chemotherapy and androgen receptor targeted therapy
• Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
• Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
• NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatmen...
• PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastat...
• Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder...
• Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
• Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second...
• Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
• Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment...
• Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on mu...

• « Previous
• 1
• 2
• ...
• 79
• Next »